Crenças, atitudes e comportamentos de saúde e de risco de adictos em comunidades terapêuticas

Os comportamentos de saúde e de risco são comuns em toxicodependentes. Este trabalho foi conduzido no âmbito da análise descritiva da amostra, nomeadamente, caracterização sócio-demográfica e variáveis cognitivas, seguindo-se um segundo objectivo que consistiu na descrição dos comportamentos, crenças e atitudes face à saúde que os adictos apresentam. A amostra é constituída por 75 sujeitos, do sexo masculino, com uma média de idade de 34,07 anos. A metodologia utilizada caracteriza o estudo de quantitativo-correlacionai, uma vez que se pretende efectuar a descrição das características da amostra e os comportamentos de saúde e de risco que apresentam. Os resultados revelam que os adictos apresentam comportamentos de risco, logo, são menores os comportamentos de saúde adoptados durante os consumos. É necessário intervir nas várias áreas de saúde do adicto, nomeadamente, nas práticas sexuais, na prevenção de doenças, nos cuidados alimentares, na conduta rodoviária e na preocupação com o exercício físico-desportivo. /ABSTRACT: Health behaviors and risk factors are common in drug addicts. This work was conducted under the descriptive analysis, including socio-demographic and cognitive variables, followed by a second objective was to describe the altitudes, beliefs and altitudes towards health that addicts have. The sample consists of 75 subjects were mala, with a mean age of 34.07 years. The methodology characterizes the quantitative and correlational study, since we intend to perform the description of sample characteristics and health behaviors and risk they present. The results show that addicts exhibit risky behavior, so they are smaller health behaviors adopted during the intake. lt is necessary to intervene in several areas of health of the addict, including sexual practices, disease prevention, care food, conduct road and the concern that physical exercise I sports.

“Biomarkers in a One Health perspective: current knowledge of their ability to merge human and animal health

Biomarkers are nowadays essential tools to be one step ahead for fighting disease, enabling an enhanced focus on disease prevention and on the probability of its occurrence. Research in a multidisciplinary approach has been an important step towards the repeated discovery of new biomarkers. Biomarkers are defined as biochemical measurable indicators of the presence of disease or as indicators for monitoring disease progression. Currently, biomarkers have been used in several domains such as oncology, neurology, cardiovascular, inflammatory and respiratory disease, and several endocrinopathies. Bridging biomarkers in a One Health perspective has been proven useful in almost all of these domains. In oncology, humans and animals are found to be subject to the same environmental and genetic predisposing factors: examples include the existence of mutations in BR-CA1 gene predisposing to breast cancer, both in human and dogs, with increased prevalence in certain dog breeds and human ethnic groups. Also, breast feeding frequency and duration has been related to a decreased risk of breast cancer in women and bitches. When it comes to infectious diseases, this parallelism is prone to be even more important, for as much as 75% of all emerging diseases are believed to be zoonotic. Examples of successful use of biomarkers have been found in several zoonotic diseases such as Ebola, dengue, leptospirosis or West Nile virus infections. Acute Phase Proteins (APPs) have been used for quite some time as biomarkers of inflammatory conditions. These have been used in human health but also in the veterinary field such as in mastitis evaluation and PRRS (porcine respiratory and reproductive syndrome) diagnosis. Advantages rely on the fact that these biomarkers can be much easier to assess than other conventional disease diagnostic approaches (example: measured in easy to collect saliva samples). Another domain in which biomarkers have been essential is food safety: the possibility to measure exposure to chemical contaminants or other biohazards present in the food chain, which are sometimes analytical challenges due to their low bioavailability in body fluids, is nowadays a major breakthrough. Finally, biomarkers are considered the key to provide more personalized therapies, with more efficient outcomes and fewer side effects. This approach is expected to be the correct path to follow also in veterinary medicine, in the near future.